Health & Environmental Research Online (HERO)


Print Feedback Export to File
710966 
Journal Article 
Inorganic arsenite inhibits IgE receptor-mediated degranulation of mast cells 
Hutchinson, LM; Trinh, BM; Palmer, RK; Preziosi, CA; Pelletier, JH; Nelson, HM; Gosse, JA 
2011 
Yes 
Journal of Applied Toxicology
ISSN: 0260-437X
EISSN: 1099-1263 
31 
231-241 
English 
Millions of people worldwide are exposed to arsenic (As), a toxicant which increases the risk of various cancers, cardiovascular disease and several other health problems. Arsenic is a potent endocrine disruptor, including of the estrogen receptor. It was recently shown that environmental estrogen-receptor disruptors can affect the signaling of mast cells, which are important players in parasite defense, asthma and allergy. Antigen (Ag) or allergen crosslinking of IgE-bound receptors on mast cells leads to signaling, culminating in degranulation, the release of histamine and other mediators. Because As is an endocrine disruptor and because endocrine disruptors have been found to affect degranulation, here we have tested whether sodium arsenite affects degranulation. Using the rat basophilic leukemia (RBL) mast cell model, we have measured degranulation in a fluorescence assay. Arsenic alone had no effect on basal levels of degranulation. However, As strongly inhibited Ag-stimulated degranulation at environmentally relevant concentrations, in a manner that is very dependent on concentrations of both As and Ag. The concentrations of As effective at inhibiting degranulation were not cytotoxic. This inhibition may be a mechanism underlying the traditional Chinese medicinal use of As to treat asthma. These data indicate that As may inhibit the ability of humans to fight off parasitic disease. 
arsenic; arsenite; mast cells; basophils; degranulation; RBL-2H3; endocrine disruptor; parasite; allergy; asthma 
• Arsenic (Inorganic)
     1. Literature
          PubMed
          Toxline, TSCATS, & DART
          Web of Science
     3. Hazard ID Screening
          Other potentially supporting studies
     4. Adverse Outcome Pathways/Networks Screening
          Relevant
• Arsenic MOA
     4. Adverse Outcome Pathways
          Endocrine mechanisms
     1. MOA Literature Screening
          Health Effect Screening
• Arsenic Susceptibility
     Life Stages Citation Mapping
          15%-20%
• Inorganic Arsenic (7440-38-2) [Final 2025]
     1. Initial Lit Search
          PubMed
          WOS
          ToxNet
     4. Considered through Oct 2015
     7. Other Studies through Oct 2015
          MOA